- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05210660
Medical Cannabis Against Chronic Musculoskeletal Pain: a Mixed Methods Study.
Medical Cannabis Against Chronic Musculoskeletal Pain: a Mixed Methods Study to Describe Use and to Identify Its Facilitators and Barriers Among Canadian Patients and Doctors
Study Overview
Status
Conditions
Detailed Description
Chronic musculoskeletal pain (CMP) is very frequent among Canadians. Pharmacological treatment options for CMP are limited, and some of them (e.g. opioids) have important adverse effects if taken for a long time. Cannabis destined for therapeutic use ("medical cannabis" - MC) could represent an interesting alternative therapeutic option for CMP; it attracts more and more attention, particularly with the legalisation of recreational cannabis in October 2018. However, past research, including that of a team member1-4 and a scoping literature review5,6 from our team, revealed severe knowledge gaps regarding many aspects of the utility and conditions of use of MC in the management of CMP, such as its effectiveness, safety, routes of administration, delivery methods, dosage, etc. The fact that cannabis is also used recreationally and linked to a strong user stigma complicates both the conduct of rigorous randomized controlled trials and the conclusions which can be drawn from prior research. We propose as a first step for the development of knowledge on the use of MC to relieve CMP to study current MC users and prescribers, as well as their personal experiences with and perceptions of MC. This will improve both continuous education for prescribers and knowledge exchange with users. The new knowledge will pave the way to the design of research trials that with improved, less biased recruitment, and a follow-up of larger numbers of participants, which in turn would improve the validity and generalisability of the results of such trials. It will thus facilitate rigorous clinical trials, which are absolutely necessary in order to develop sufficient knowledge on this topic. To this end, we propose a mixed methods study that will aim to: 1)Describe the use of MC in the management of CMP in Quebec and Canada, its recent evolution as well as the main characteristics of its users and prescribers; 2)Identify the therapeutic and adverse effects of MC as experienced by patients with CMP enrolled in the QCR; 3a)Identify the psychosocial, organizational, sociodemographic and disease-related factors influencing MC use in patients and prescribers; and 3b)Quantify the influence of these factors on the use of MC in the management of CMP.
The proposed study will use mixed, quantitative and qualitative, methods. The first component (Objectives 1 and 2) will take advantage of Canadian databases, including the QCR, to describe the extent of MC use in Canada, MC authorised users and their prescribers. The second component (Objectives 3a and 3b) will use a qualitative and quantitative methodology to identify the factors influencing the use of MC by patients suffering from CMP and the prescription of MC by their doctors. The new scientific knowledge generated by this study will be shared in the form of publications, policy briefs to guide patients and prescribers on the use of the MC in the management of CMP and recommendations guiding the conduct of rigorous clinical trials that will take into account the needs of Canadian patients and physicians.
In order to benefit from the presence of experts who will be able to guide and orient the work, validate the research results and facilitate the appropriation and exchange of knowledge, a steering committee will accompany the research activities from the onset of the second part of the study. This committee will be composed of clinicians anaesthesiologists, family physicians, pharmacists, rheumatologists), of patients suffering from CMP who are using and not using MC, of representatives of CMP societies (e.g.
The Arthritis Society), of decision-makers (ICES, INESSS, INSPQ), of the cannabis industry (e.g. Canopy Growth Corporation) and of researchers from the team. Professionals from the SRAP ("Strategy for Patient-Oriented Research") initiative of CIHR will accompany the team for the final identification of committee members, particularly patient members. A knowledge broker will be in charge of the animation of these meetings. This person will be responsible for the main aspects of knowledge translation, i.e. the preparation of the communication strategies with the different audiences. Three meetings are planned, during pivotal moments of the project: Meeting 1: Component 1 review (presentation of Component 1 results) / initiation of Component 2: validation of the research strategy for the collection of exploratory qualitative data (interview guide); Meeting 2: Presentation of the results of the qualitative component (Objective 3a) / Work on the research strategy for collecting quantitative data (questionnaire) (Objective 3 b); Meeting 3: Members will work on the recommendations and guidance notes for knowledge translation.
The proposed study aims to describe the current use of CM against CMP in Quebec and Canada and will help to better understand the motivations and expectations of physicians and patients. This new knowledge will enable the design of future high quality RCTs and provide stakeholders with guidelines for the use of MC for musculoskeletal pain.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Edeltraut Kröger, Ph.D.
- Phone Number: 84834 418 682-7511
- Email: edeltraut.kroger.ciussscn@ssss.gouv.qc.ca
Study Locations
-
-
-
Québec, Canada, G1S 4L8
- Recruiting
- Hopital du St-Sacrement
-
Contact:
- Lise Poisblaud
- Email: lise.poisblaud@crchudequebec.ulaval.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The study population for the qualititive part of the project is divided as follow:
30 patients, including at least 10 using medical cannabis, 15 physicians who follow patients with chronic musculoskeletal pain, including at least 5 physician who prescribe or have prescribed medical cannabis
Description
Inclusion Criteria patients (N=30):
- 18 years old or older
- Able to consent
- Understand and speak French to be autonomous during the interview
- Have chronic musculoskeletal pain (at least for the last 3 months)
- OPTIONAL: have used medical cannabis against chronic musculoskeletal pain (for 10/30 recruited patients)
Inclusion Criteria physicians (N=15):
- Hold a right to practice medicine in Canada
- Practice medicine at the time of the research project
- Understand and speak French to be autonomous during the interview
- Follow patients with chronic musculoskeletal pain
- OPTIONAL: Prescribe or have prescribed medical cannabis for chronic musculoskeletal pain (only for 5/15 recruited family physicians)
Exclusion Criteria:
There is no specific exclusion criteria. Participants who do not meet the inclusion criteria will be excluded from the study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Use of any medical cannabis (MC) against chronic musculoskeletal pain (CMP)
Time Frame: Use during the last month: cross sectional study
|
Describe the current use of MC against CMP
|
Use during the last month: cross sectional study
|
Authorization of any MC against CMP by a physician
Time Frame: Use during the last month: cross sectional study
|
Describe the current authorization of MC against CMP
|
Use during the last month: cross sectional study
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Edeltraut Kröger, Ph.D., CHU de Quebec-Universite Laval
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 411197
- CU2-163003 (Other Grant/Funding Number: Canadian Institutes of Health Research)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Musculoskeletal Pain
-
Sykehuset i Vestfold HFActive, not recruitingBack Pain | Musculoskeletal Pain | Chronic Pain | Musculoskeletal Diseases or Conditions | Pain, Chronic | Musculoskeletal Disorder | Musculoskeletal Neck PainNorway
-
University of Missouri, Kansas CityTerminatedOrthopaedic Related Pain (Musculoskeletal Pain)United States
-
Uppsala UniversityDalarna County Council, Sweden; Center for Clinical Research Dalarna, Sweden; REHSAM, SwedenTerminatedMusculoskeletal Neck Pain | Musculoskeletal Shoulder PainSweden
-
NORCE Norwegian Research Centre ASHelse Sor-Ost; Sykehuset i Vestfold HFCompletedNeck Pain Musculoskeletal | Back Pain Lower BackNorway
-
Massachusetts General HospitalOrthopaedic Trauma AssociationCompleted
-
Stanford UniversityNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingPain | Joint Pain | Pain, Chronic | Chronic Musculoskeletal PainUnited States
-
University of North Carolina, Chapel HillYale University; Duke University; National Institute on Aging (NIA); Indiana University and other collaboratorsCompletedChronic Pain | Acute Musculoskeletal PainUnited States
-
Wayne State UniversityUniversity of MichiganCompleted
-
Wayne State UniversityBlue Cross Blue Shield of Michigan FoundationCompleted
-
Wayne State UniversityUniversity of Southern CaliforniaCompleted